Torres Vicente E, Ahn Curie, Barten Thijs R M, Brosnahan Godela, Cadnapaphornchai Melissa A, Chapman Arlene B, Cornec-Le Gall Emilie, Drenth Joost P H, Gansevoort Ron T, Harris Peter C, Harris Tess, Horie Shigeo, Liebau Max C, Liew Michele, Mallett Andrew J, Mei Changlin, Mekahli Djalila, Odland Dwight, Ong Albert C M, Onuchic Luiz F, Pei York P-C, Perrone Ronald D, Rangan Gopala K, Rayner Brian, Torra Roser, Balk Ethan M, Gordon Craig E, Earley Amy, Mustafa Reem A, Devuyst Olivier
Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Laboratory of Transplantation Immunology, Seoul National University, Seoul, South Korea.
Kidney Int. 2025 Feb;107(2):234-254. doi: 10.1016/j.kint.2024.07.010.
The Kidney Disease: Improving Global Outcomes (KDIGO) 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) represents the first KDIGO guideline on this subject. Its scope includes nomenclature, diagnosis, prognosis, and prevalence; kidney manifestations; chronic kidney disease (CKD) management and progression, kidney failure, and kidney replacement therapy; therapies to delay progression of kidney disease; polycystic liver disease; intracranial aneurysms and other extrarenal manifestations; lifestyle and psychosocial aspects; pregnancy and reproductive issues; pediatric issues; and approaches to the management of people with ADPKD. The guideline has been developed with patient partners, clinicians, and researchers around the world, with the goal to generate a useful resource for healthcare providers and patients by providing actionable recommendations. The development of this guideline followed an explicit process of evidence review and appraisal, based on a rigorous, formal systematic literature review. The strength of recommendations follows the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. The guideline also provides practice points serving to direct clinical care or activities relating to areas for which a systematic review was not conducted. Limitations of the evidence are discussed. Research recommendations to address gaps in knowledge, and implications for policy and payment, are provided. The guideline targets a broad audience of healthcare providers, people living with ADPKD, and stakeholders involved in the various aspects of ADPKD care.
《肾脏疾病：改善全球预后（KDIGO）2025年常染色体显性多囊肾病（ADPKD）评估、管理与治疗临床实践指南》是KDIGO关于该主题的首份指南。其范围包括命名法、诊断、预后和患病率；肾脏表现；慢性肾脏病（CKD）管理与进展、肾衰竭及肾脏替代治疗；延缓肾病进展的疗法；多囊肝病；颅内动脉瘤及其他肾外表现；生活方式和心理社会方面；妊娠和生殖问题；儿科问题；以及ADPKD患者的管理方法。该指南是与全球的患者伙伴、临床医生和研究人员共同制定的，目标是通过提供可操作的建议，为医疗服务提供者和患者生成一份有用的资源。本指南的制定遵循了明确的证据审查和评估流程，基于严格、正式的系统文献综述。推荐强度遵循推荐评估、制定与评价分级（GRADE）方法。该指南还提供了实践要点，用于指导临床护理或与未进行系统综述的领域相关的活动。讨论了证据的局限性。提供了针对知识空白的研究建议以及对政策和支付的影响。该指南面向广泛的受众，包括医疗服务提供者、ADPKD患者以及参与ADPKD护理各个方面的利益相关者。
